PHILADELPHIA – The Biotechnology Industry Organization's (BIO) International Convention returns to the City of Brotherly Love this week after a decade since BIO 2005 convened here.
PHILADELPHIA – In a media briefing, Jim Greenwood, president and CEO of the Biotechnology Industry Organization (BIO), said the industry will be heading into the BIO 2015 International Convention on a record-setting high.
PHILADELPHIA – The Biotechnology Industry Organization's (BIO) International Convention returns to the City of Brotherly Love this week after a decade since BIO 2005 convened here. In the period that has elapsed between events, the industry is hardly recognizable to what it was way back in 2005.
Priority review vouchers (PRVs) are intended to encourage the development of new therapies for underserved disease areas, such as tropical diseases and rare pediatric diseases by shaving four months off the normal 10-month period the FDA takes to conduct its drug review.
In the first part of our analysis on the public biopharmaceutical companies presenting data at the ASCO meeting, covering the week the conference abstracts were released (May 11 - 15), we discovered that overall those abstract data did help improve company stock valuations, and, as a group, an average 3.2 percent increase in share price was recorded.
The "sell in May and go away" investing strategy was totally ignored by investors focused on biotech. As a result, it turned out to be another great month for the sector with its blue chip companies leading the charge once again.
While it is still early days, the microbiome space is heating up with a number of biotech start-ups appearing on the scene over the past 12 months. Cambridge, Mass.-based Seres Therapeutics Inc. is hoping to capitalize on that rising tide of investor interest by filing its S-1 registration statement with the SEC to raise up to $100 million in an IPO.
The release of the American Society of Clinical Oncology (ASCO) annual meeting abstracts has become almost as much of an anticipated event by Wall Street, analysts, media and the biopharmaceutical industry as the meeting itself, which this year runs May 29-June 2 in Chicago.
Migraine is a complex neurological phenomenon manifesting in painful headaches that can be extremely debilitating which, according to the World Health Organization, ranks it in the top four disabling neurological conditions affecting almost 20 percent of the world's population.
SAN FRANCISCO – One of the takeaway messages for delegates attending the recent Allicense 2015 meeting was that M&As remain on a tear right now and it is predicted that their numbers are likely to outpace last year's record transactions.
